Navigation Links
Catalent’s Clinical Trial Supply Facility in Shanghai, China Opens for Business

Somerset, NJ (PRWEB) November 13, 2013

Catalent Pharma Solutions, the global leader in development solutions and advanced delivery technologies for drug, biologic and consumer health products, today announced that construction and validation of its Clinical Supply facility in Shanghai, China has been completed. Catalent business leaders, local employees, customers and partners celebrated at a site opening ceremony on November 8th, 2013, less than 9 months after construction began on the site.

It is the first clinical supply facility in China to provide end-to-end clinical supply solutions from clinical supply management, comparator sourcing and primary packaging to storage and distribution. The facility is also validated to support biologics requiring refrigerated and frozen supply chain management. Catalent has already secured customer projects for the site, which is now undergoing customer validation for the supply of clinical trial materials.

Catalent currently supports the clinical trial supply needs of the top 25 pharmaceutical companies and more than 300 small innovators from all over the world. The new, state-of-the-art, 31,000 square foot facility has been constructed to the company’s proven ‘center of excellence’ guidelines and will operate to Catalent’s global Quality Management System. The Catalent (Shanghai) Clinical Trial Supplies Co., Ltd. facility is the eighth in Catalent’s global clinical supply network and is located in Shanghai’s Waigaoqiao Free Trade Zone.

“China is a fast growing market for the pharmaceutical industry and a market that Catalent will continue to invest in,” commented Scott Houlton, President of Development and Clinical Services at Catalent. “Having started work on our China clinical supply strategy two years ago, I’m excited to see this strategy implemented and the new site open for business. It is a great addition to Catalent’s global clinical supply network and will help to better serve our customers increasing need for clinical trials in Asia.”

Dr. Weiyan “Jackson” Zhu, Catalent's Country General Manager for China added, “The recently appointed local management team brings a huge combined prior experience of clinical trials management, pharmaceuticals and healthcare. Together with Catalent’s GMP facility in Singapore, the company is well positioned to serve the clinical trials needs of our regional and global customers.”

About Catalent
Catalent Pharma Solutions is the global leader in development solutions and advanced drug delivery technologies, providing world-wide clinical and commercial supply capabilities for drugs, biologics and consumer health products. With over 75 years serving the industry, Catalent has proven expertise in bringing more customer products to market faster, enhancing product performance and ensuring reliable product supply. Catalent employs approximately 8,500 people, including over 1,000 scientists, at nearly 30 facilities across 5 continents and generates more than $1.7 billion in annual revenue. Catalent is headquartered in Somerset, N.J. For more information, visit

More products. Better treatments. Reliably supplied.™

Useful Links
June 20, 2013: “Catalent Officially Launches New Capabilities at CPhI China”
April 16, 2013: “Catalent Announces Two Senior Appointments to Drive Growth in China”
March 11, 2013: ”Catalent Announces Major China Expansion with Two New Facilities for Softgel Technologies and Clinical Supply Solutions Businesses”

Catalent’s location in Shanghai and capabilities.

Read the full story at

Source: PRWeb
Copyright©2012 Vocus, Inc.
All rights reserved

Related medicine news :

1. Clinical trial finds concurrent therapy not necessary to achieve high pathological in breast cancer
2. Nemours receives Dept. of Defense award to study physicians maintenance of optimal clinical program
3. Clinical trial looks at impact of platelet-rich plasma therapy on tennis elbow
4. The DelRay Recovery Center Appoints Britt Bonner as the Director of Clinical Outreach
5. Salar Joins Medical Informatics Experts to Judge AMIA’s First Ever Student Design Challenge: Reinventing Clinical Documentation
6. Kidney Week 2013: New innovations in clinical science
7. Pre-Diabetes/Impaired Glucose Tolerance Global Clinical Trials Review, H2, 2013
8. Gastrointestinal Bleeding Market: Global Clinical Trials Review H2 2013 in New Research Report at
9. Proactol Plus - Clinically Proven Weight Loss Pills Now Offers 1 Month Extra Supply on Select Packages
10. Contract Research Organization WCCT Global Welcomes Edward Kim as Executive Director, Early Clinical Development
11. $100 million gift launches Sanford Stem Cell Clinical Center
Post Your Comments:
(Date:12/1/2015)... ... December 01, 2015 , ... For the ... is why Hollister Incorporated has launched the VaPro Plus Pocket™ touch free hydrophilic ... the VaPro touch free catheter portfolio,” said Michael Gresavage, Vice President North America. ...
(Date:12/1/2015)... ... ... McLean, VA., December 1, 2015 - Octo Consulting Group, ... development contract to support the National Geospatial-Intelligence Agency's (NGA) IT Services Directorate. ... as well as operations and sustainment support to the NGA’s Agile Web Presence ...
(Date:12/1/2015)... ... ... XTC Semifinals 2016 - CES, Las Vegas, Nevada - Extreme ... 2016, the world’s largest Consumer Electronic Show, where they will present to a panel ... Pacific Investments Veronica Serra, and venture capitalist Tim Draper among many other top names ...
(Date:12/1/2015)... ... December 01, 2015 , ... Dr. Arash ... Modern Man for 2015. , Angeleno Magazine is a division of Modern ... in 1994, Modern Luxury includes more than 50 magazine titles across 15 major ...
(Date:11/30/2015)... ... 2015 , ... Olympic Gold Medalists and Celebrity Moms Dara ... various categories through traditional and social media marketing campaigns and other branding initiatives. ... Medal Moms who can connect with today’s most important consumer: mothers. In addition ...
Breaking Medicine News(10 mins):
(Date:12/1/2015)... -- ) has announced ... Market 2015 - Forecast to 2020" report ... has announced the addition of the "Drug ... report to their offering. --> ... the addition of the "Drug Delivery Technology ...
(Date:12/1/2015)... Sweden , December 1, 2015 ... Cancer Study Group (IBCSG, Bern ) and ... to be part of a state of the art trial, ... --> --> The study, ... treated with anti-hormonal therapy in combination with palbociclib, a cancer ...
(Date:11/30/2015)... BASEL, Switzerland , Dec. 1, 2015 /PRNewswire/ ... its wholly-owned UK subsidiary Proximagen Ltd., today announced a ... oral small molecule inhibitor of Vascular Adhesion Protein 1 ... the treatment of inflammatory disease. The VAP-1 inhibitor is ... --> --> Under the terms of ...
Breaking Medicine Technology: